Current Cancer Drug Targets

Editor-in-Chief:

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
USA

Back

Become EABM
Become Reviewer

Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics

Volume:10   Issue: 4
Pp: 354-367
M.R. Pitman and S.M. Pitson
DOI: 10.2174/156800910791208599

Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent

Volume:10   Issue: 4
Pp: 368-383
L. Tentori, A. Muzi, A.S. Dorio, M. Scarsella, C. Leonetti, G.M. Shah, W. Xu, E. Camaioni, B. Gold, R. Pellicciari, F. Dantzer, J. Zhang and G. Graziani
DOI: 10.2174/156800910791208571

Targeting CREB for Cancer Therapy: Friend or Foe

Volume:10   Issue: 4
Pp: 384-391
X. Xiao, B.X. Li, B. Mitton, A. Ikeda and K.M. Sakamoto
DOI: 10.2174/156800910791208535

Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer

Volume:10   Issue: 4
Pp: 392-401
B. Wegiel, S. Evans, R. Hellsten, L.E. Otterbein, A. Bjartell and J.L. Persson
DOI: 10.2174/156800910791208562

Recent Advances in Understanding Hormonal Therapy Resistant Prostate Cancer

Volume:10   Issue: 4
Pp: 402-410
K.V. Donkena, H. Yuan and C.Y. Young
DOI: 10.2174/156800910791208544

Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy

Volume:10   Issue: 4
Pp: 411-421
S. Cruet-Hennequart, A.M. Prendergast, F.P. Barry and M.P. Carty
DOI: 10.2174/156800910791208553

Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells

Volume:10   Issue: 4
Pp: 422-431
S. Carloni, F. Fabbri, G. Brigliadori, P. Ulivi, R. Silvestrini, D. Amadori and W. Zoli
DOI: 10.2174/156800910791208580